


SUPPLEMENTARY INFORMATION

1. Synthesis of Alverine (**1**)

The synthesis of alverine (**1**) was carried out according to the procedure previously described by Shakhmaev et al.¹

1a. Synthesis of (2*E*)-3-chloro-*N*-[(2*E*)-3-chloroprop-2-en-1-yl]-*N*-ethylprop-2-en-1-amine (**3**)



(*E*)-1,3-dichloropropene (**2**) (0.46 mL, 4.5 mmol), K_2CO_3 (1.050 g, 7.5 mmol) and $\text{EtNH}_2 \cdot \text{HCl}$ (0.193 g, 2.3 mmol) were dissolved in anhydrous MeCN (5.6 mL). The reaction mixture was allowed to stir at 100 °C for 16 h until the end of the reaction, as indicated by t.l.c. ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 5%). The suspension was cooled down to room temperature, filtered and the solvent was removed under reduced pressure. The product was isolated by distillation by heating under high vacuum (2×10^{-1} Pa) to obtain (2*E*)-3-chloro-*N*-[(2*E*)-3-chloroprop-2-en-1-yl]-*N*-ethylprop-2-en-1-amine (**3**) as a yellowish liquid (0.40 g, 90%).

NMR-¹H (400 MHz, δ_{H} , CDCl_3): δ = 6.16 (d, $J_{\text{H-H}}=13.3$ Hz, 2H, H-3), 5.98 (m, 2H, H-2), 3.14 (d, $J_{\text{H-H}}=6.8$ Hz, 4H, H-1), 2.56 (q, $J_{\text{H-H}}=7.0$ Hz, 2H, $\text{CH}_3\text{CH}_2\text{N}$), 1.13 (t, $J_{\text{H-H}}=7.1$ Hz, 3H, $\text{CH}_3\text{CH}_2\text{N}$).

NMR-¹³C (100.6 MHz, δ_{C} , CDCl_3): δ = 130.5 (C-2), 120.0 (C-3), 52.8 (C-1), 46.9 ($\text{CH}_3\text{CH}_2\text{N}$), 12.0 ($\text{CH}_3\text{CH}_2\text{N}$).




Figure S1. NMR- ^{13}C of (*2E*)-3-chloro-*N*-[(*2E*)-3-chloroprop-2-en-1-yl]*N*-ethylprop-2-en-1-amine (**3**)





Figure S2. NMR- ^1H of (*2E*)-*N*-ethyl-3-phenyl-*N*-[(*2E*)-3-phenylprop-2-en-1-yl]prop-2-en-1-amine (**4**)

1b. Synthesis of (2E)-N-ethyl-3-phenyl-N-[(2E)-3-phenylprop-2-en-1-yl]-prop-2-en-1-amine (4)



Fe(acac)₃ (0.012 g, 0.03 mmol) was dissolved in dry THF (1 mL) and added to a solution of **3** (0.306 g, 1.55 mmol) at 0 °C and in an inert atmosphere. Next was added TMEDA (0.03 mL, 0.15 mmol) and PhMgBr (2 mL, 3.2 mmol). The mixture was stirred at room temperature for 2 h until the end of the reaction, as indicated by t.l.c. (Hex/AcOEt 2:1). Water was then added (2mL) and the crude was extracted with AcOEt (3 x 7 mL). The organic phases were collected and washed with saturated aqueous solution of NaCl, dried with anhydrous Na₂SO₄ and concentrated via rotary evaporation. Finally, the product was isolated by column chromatography using as eluent Hex/AcOEt (2:1) obtaining a yellow liquid (**4**, 0.24 g, 55%).

RMN-¹H (400 MHz, δ_H, CDCl₃): δ= 7.43-7.26 (m, 10H, H-Ar), 6.58 (d, J_{H-H}=15.8 Hz, 2H, H-3), 6.35 (m, 2H, H-2), 3.38 (d, J_{H-H}=6.8 Hz, 4H, H-1), 2.71 (m, 2H, CH₃CH₂N), 1.17 (t, J_{H-H}=7.1 Hz, 3H, CH₃CH₂N).

RMN-¹³C (100.6 MHz, δ_C, CDCl₃): δ= 137.0 (C-4), 133.1 (C-3), 128.6 (C-5,6,8,9), 127.5 (C-2), 126.3 (C-7), 55.7 (C-1), 47.2 (CH₃CH₂N), 11.7 (CH₃CH₂N).



Figure S3. NMR-¹H of (2*E*)-*N*-ethyl-3-phenyl-*N*-[(2*E*)-3-phenylprop-2-en-1-yl]prop-2-en-1-amine (**4**)





Figure S4. NMR-¹³C of (2*E*)-*N*-ethyl-3-phenyl-*N*-[(2*E*)-3-phenylprop-2-en-1-yl]prop-2-en-1-amine (**4**)


1c. Synthesis of Alverine (*N*-ethyl-3-phenyl-*N*-(3-phenylpropyl)propan-1-amine, **1**)



A solution of NaOH 0.1M in EtOH 95% (1.8 mL) was added to Pd/C 10% (5 mg) and **4** (0.1 g, 0.36 mmol). This suspension was stirred under an atmosphere of H_2 for 5 h until the end of the reaction, as indicated by t.l.c. (Hex/AcOEt 2:1). The mixture was filtered, concentrated and purified by column chromatography using as eluent Hex/AcOEt (9:1). The product was isolated as a yellow liquid (**1**, 0.124 g, 72%).

RMN- ^1H (400 MHz, δ_{H} , CDCl_3): δ = 7.34-7.21 (m, 10H, PhH), 2.67 (t, $J_{\text{H-H}}=7.6$ Hz, 4H, H-3), 2.61-2.50 (m, 6H, $\text{CH}_3\text{CH}_2\text{N}$, H-1), 1.82 (m, 4H, H-2), 1.05 (t, $J_{\text{H-H}}=7.1$ Hz, 3H, $\text{CH}_3\text{CH}_2\text{N}$).

RMN- ^{13}C (100.6 MHz, δ_{C} , CDCl_3): δ = 142.4 (C-4), 128.4 (C-6,8), 128.3 (C-5,9), 125.7 (C-7), 53.0 (C-1), 47.5 ($\text{CH}_3\text{CH}_2\text{N}$), 33.8 (C-3), 28.8 (C-2), 11.7 ($\text{CH}_3\text{CH}_2\text{N}$).



re S5. NMR- ^1H of alverine (**1**)

Fig





Figure S6. NMR- ^{13}C of alverine (**1**)

2. Synthesis of Alverine-based ILs

General procedure: Alverine (**1**) and an equivalent amount of the corresponding acid (*p*-toluenesulfonic acid, salicylic acid and benzoic acid) were allowed to stir at 100 °C for 2 h.

2a. Synthesis of alverinium tosylate [ALV][TOS] (**5**)



The general procedure using *p*-toluenesulfonic acid (0.072 g, 0.37 mmol) was applied. The product was obtained as a solid (**5**, 0.168 g, 99%); mp 65-66 °C (from MeOH)

RMN- ^1H (400 MHz, δ_{H} , CDCl_3): δ = 7.80 (d, $J_{\text{H-H}}$ =8.1 Hz, 2H, H-2 TOS, H-6 TOS), 7.32-7.16 (m, 12H, H-Ar), 5.03 (s, 1H, NH), 2.81 (m, 2H, $\text{CH}_3\text{CH}_2\text{N}$), 2.71 (t, $J_{\text{H-H}}$ =8.0 Hz, 4H, H-1 ALV), 2.65 (t, $J_{\text{H-H}}$ =7.5 Hz, 4H, H-3 ALV), 2.38 (s, 3H, CH_3 TOS), 1.90 (m, 4H, H-2 ALV), 1.11 (t, $J_{\text{H-H}}$ =7.2 Hz, 3H, $\text{CH}_3\text{CH}_2\text{N}$).

RMN-¹³C (100.6 MHz, δ_C, CDCl₃): 142.4 (C-1 TOS, C-4 TOS), 139.9 (C-4 ALV), 129.0 (C-3 TOS, C-5 TOS), 128.6 (C-6 ALV, C-8 ALV), 128.5 (C-5 ALV, C-9 ALV, C-2 TOS, C-6 TOS), 125.9 (C-7 ALV), 53.0 (C-1 ALV), 47.6 (CH₃CH₂N), 33.9 (C-3 ALV), 28.7 (CH₃ TOS), 21.5 (C-2 ALV), 11.7 (CH₃CH₂N).

HRMS (ESI) *m/z* (%): calcd for [C₂₀H₂₈N]⁺: 282.2219 [M]⁺; found 282.2216 (100); calcd for [C₁₄H₁₅O₆S₂]⁻: 343.0316 [M]⁻; found: 343.0316 (100).




Figure S7. NMR-¹H of alverinium tosylate [ALV][TOS] (**5**)





Figure S8. NMR-¹³C of alverinium tosylate [ALV][TOS] (**5**)

2b. Synthesis of alverinium salicylate [ALV][SAL] (**6**)





General procedure was applied using salicylic acid (0.050 g, 0.37 mmol) to obtain a yellow liquid (**6**, 0.119 g, 99%).


RMN-¹H (400 MHz, δ_{H} , CDCl₃): δ = 7.93 (d, $J_{\text{H-H}}$ =7.9 Hz, 1H, H-7 SAL), 7.29 (m, 5H, H-6 ALV, H-8 ALV, H-5 SAL), 7.23 (t, $J_{\text{H-H}}$ =7.1 Hz, 2H, H-7 ALV), 7.16 (d, $J_{\text{H-H}}$ =7.3 Hz, 4H, H-5 ALV, H-9 ALV), 6.94 (d, $J_{\text{H-H}}$ =8.1 Hz, 1H, H-4 SAL), 6.84 (t, $J_{\text{H-H}}$ =7.4 Hz, 1H, H-6 SAL), 3.12 (q, $J_{\text{H-H}}$ =7.3 Hz, 2H, CH₃CH₂N), 2.99 (m, 4H, H-1 ALV), 2.69 (t, $J_{\text{H-H}}$ =7.2 Hz, 4H, H-3 ALV), 2.03 (m, 4H, H-2 ALV), 1.23 (t, $J_{\text{H-H}}$ =7.2 Hz, 3H, CH₃CH₂N).

RMN-¹³C (100.6 MHz, δ_{C} , CDCl₃): δ = 174.9 (C-1 SAL), 162.1 (C-3 SAL), 140.7 (C-4 ALV), 132.8 (C-5 SAL), 130.8 (C-7 SAL), 128.6 (C-6 ALV, C-8 ALV), 128.4 (C-5 ALV, C-9 ALV), 126.3 (C-7 ALV), 119.1 (C-2 SAL), 117.8 (C-6 SAL), 116.5 (C-4 SAL), 51.3 (C-1 ALV), 46.9 (CH₃CH₂N), 33.1 (C-3 ALV), 26.0 (C-2 ALV), 9.6 (CH₃CH₂N).

HRMS (ESI) m/z (%): calcd for $[C_{20}H_{28}N]^+$: 282.2218 $[M]^+$; found 282.2216 (100); calcd for $[C_7H_5O_3]^-$: 137.0238 $[M]^-$; found 137.0244 (100).



2c. Synthesis of alverinium benzoate [ALV][BNZ] (**7**)



General procedure was applied using benzoic acid (0.043 g, 0.35 mmol) to obtain an orange liquid (**7**, 0.106 g, 99%).

RMN-¹H (400 MHz, δ_{H} , CDCl₃): δ = 8.10 (m, 1H, H-5 BNZ), 7.43 (m, 2H, H-3 BNZ, H-7 BNZ), 7.30 (m, 6H, H-Ar), 7.22 (m, 6H, H-Ar), 2.90 (q, $J_{\text{H-H}}$ = 7.2 Hz, 2H, CH₃CH₂N), 2.81 (m, 4H, H-1 ALV), 2.67 (t, $J_{\text{H-H}}$ = 7.5 Hz, 4H, H-3 ALV), 1.96 (m, 4H, H-2 ALV), 1.16 (t, $J_{\text{H-H}}$ = 7.2 Hz, 3H, CH₃CH₂N).

RMN-¹³C (100.6 MHz, δ_{C} , CDCl₃): δ = 172.2 (C-1 BNZ), 140.5 (C-4 ALV), 135.7 (C-2 BNZ), 130.9 (C-3,5,7 BNZ), 129.6 (C-4 BNZ, C-6 BNZ), 128.6 (C-6 ALV, C-8 ALV), 128.3 (C-5 ALV, C-9 ALV), 126.3 (C-7 ALV), 50.6 (C-1 ALV), 46.4 (CH₃CH₂N), 33.1 (C-3 ALV), 25.2 (C-2 ALV), 9.0 (CH₃CH₂N).

HRMS (ESI) m/z (%): calcd for [C₂₀H₂₈N]⁺: 282.2215 [M]⁺; found 282.2216 (100); calcd for [C₇H₅O₂]⁻: 121.0290 [M]⁻; found 121.0295 (100).




Figure S11. NMR-¹H of alverinium benzoate [ALV][BNZ] (**7**)




Figure S12. NMR-¹³C of alverinium benzoate [ALV][BNZ] (**7**)

REFERENCES

1. R. N. Shakhmaev, A. Sh. Sunagatullina and V.V. Zorin, *Russ. J. Org. Chem.*, 2017, **53**, 832–835.